TriSalus Life Sciences, Inc.

MedTech Acquisition Corp (Nasdaq: MTAC) is a blank check company that completed its initial public offering in 2021 with a focus on the healthcare and medical technology sector. Sponsored by MedTech Acquisition Sponsor LLC, MTAC filed a Form 10-Q with the SEC on August 16, 2021, covering its activities as a pre-combination special purpose acquisition company. The vehicle later announced a definitive merger agreement with TriSalus Life Sciences, Inc., a commercial-stage oncology company specializing in pressure-enabled drug delivery systems. The de-SPAC transaction ultimately closed in 2022, transitioning MTAC into an operating medical device business. Sign up at SpacDesk for complete filings, timeline data, and sponsor analytics on MTAC and hundreds of other SPACs.